Are you Dr. Connolly?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 16 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
600 N Wolfe St
Baltimore, MD 21287Phone+1 410-955-1963- Is this information wrong?
Summary
- Dr. Roisin Connolly, MD is an oncologist in Baltimore, Maryland. She is currently licensed to practice medicine in Maryland. She is an Assistant Professor of Oncology at Johns Hopkins University School of Medicine.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2008 - 2011
University College of Dublin National Univ SOMClass of 2001
Certifications & Licensure
MD State Medical License 2010 - 2020
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Start of enrollment: 2011 Dec 01
- HKI-272 for HER2-Positive Breast Cancer and Brain Metastases Start of enrollment: 2012 Feb 01
- Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Start of enrollment: 2012 Jun 12
- Join now to see all
Publications & Presentations
PubMed
- Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.Roisin M Connolly, Victoria Wang, David M Hyman, Petros Grivas, Edith P Mitchell, John J Wright, Elad Sharon, Robert J Gray, Lisa M McShane, Larry V Rubinstein, David ...> ;Clinical Cancer Research. 2024 Apr 1
- Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial.Roussos Torres, E., Ho, W., Danilova, L., Tandurella, J., Leatherman, J., Rafie, C., Wang, C., Brufsky, A., LoRusso, P., Chung, V., Yuan, Y., Downs, M., O'Connor, A., ...> ;Nature Cancer. 2024 Feb 14
- 7 citationsThe PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.Jason J Luke, Manish R Patel, George R Blumenschein, Erika Hamilton, Bartosz Chmielowski, Susanna V Ulahannan, Roisin M Connolly, Cesar A Santa-Maria, Jie Wang, Shakee...> ;Nature Medicine. 2023 Nov 1
- Join now to see all
Press Mentions
UCC Cancer Research Aims to Individualise Treatment for Patients with Early-Stage Breast CancerOctober 18th, 2022- New Research Aims to Advance Personalisation of Treatment of Early-Stage Breast CancerSeptember 15th, 2022
- HRB €21M Cancer Clinical Trials Investment to Transform Cancer Care in IrelandDecember 17th, 2021
- Join now to see all
Professional Memberships
- Member
Other Languages
- French, German
